- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Olema Pharmaceuticals Inc Palazestrant Phase 2 Monotherapy Clinical Update Presentation TranscriptOct 23, 2023
- Olema Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Olema Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Olema Pharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) TranscriptApr 14, 2022
- Olema Pharmaceuticals Inc to Review the Phase 1 Clinical Data for OP-1250 TranscriptNov 30, 2021
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Right. Hi, everyone. Thanks so much again for joining us on day three of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach. I'm one of the research analysts here at Oppenheimer.
And the final presenting company here for today is Olema Pharmaceuticals, which is developing OP-1250, a novel endocrine receptor targeted medicine for ER-positive/HER2-negative breast cancer. Joining us to walk us through the story is the company's President and CEO, Sean Bohen. (Operator Instructions) And with that said, let's dive right into the presentation. Sean, the mic is yours.
Thank you very much, Mark. And thank you, everyone, at the end of a long day for those of you participating, for taking the time to learn about Olema and hanging in there with us.
So Olema is a company that is based on advancing therapies for cancers occurring primarily in women. And as Mark mentioned, our lead molecule, our sole clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)